Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.
Br J Cancer
; 121(2): 109-116, 2019 07.
Article
en En
| MEDLINE
| ID: mdl-31182765
Bevacizumab is an anti-vascular endothelial growth factor monoclonal antibody that may prolong survival in ovarian and cervical cancer when given in combination with chemotherapy. It works by blocking the signalling pathways that are required for tumour angiogenesis, potentially limiting the cancer's ability to grow and spread. Hypertension is a known side effect of all angiogenesis inhibitors and could lead to interruption or premature discontinuation of effective anti-cancer treatment. Hypertension may also act as a barrier to the initiation of such treatment. In this review, we aim to present clear and practical recommendations on the management of blood pressure in ovarian and cervical cancer patients before, during and after bevacizumab treatment. This guidance covers considerations before initiating bevacizumab therapy and recommendations on the management of patients who develop hypertension, or who experience worsening of pre-existing hypertension, during bevacizumab treatment, and once the course of bevacizumab has been completed. These recommendations were developed collaboratively by a group of clinicians, comprising cardiologists, oncologists, a general practitioner and specialist oncology nurses, with expertise and practical experience in either oncology or hypertension. The aim of these recommendations is to support oncologists with hypertension assessment and management to facilitate starting or continuing bevacizumab.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
/
Neoplasias del Cuello Uterino
/
Inhibidores de la Angiogénesis
/
Bevacizumab
/
Hipertensión
Tipo de estudio:
Guideline
Límite:
Female
/
Humans
Idioma:
En
Revista:
Br J Cancer
Año:
2019
Tipo del documento:
Article
Pais de publicación:
Reino Unido